Topera lands CE Mark approval in the European Union and 510(k) clearance from the FDA for its FIRMap catheter for use in mapping cardiac arrhythmias.
Topera said it landed a pair of regulatory wins for its FIRMap catheter.
The Palo Alto, Calif.-based medical device company said it won the CE Mark approval in the European Union and 510(k) clearance from the FDA for the device.
Electrograms captured by the FIRMap catheter are mapped by the already-approved RhythmView 3D mapping workstation, providing electrophysiologists with a "dynamic representation" of the heart's electrical activity for the treatment of arrhythmias, according to the press release.
"This FDA clearance and the recently received international CE Marks for both FIRMap and RhythmView represent a series of significant milestones for Topera. With this product now commercially available, we are able to offer our panoramic diagnostic catheter with our next-generation 3D mapping system. We believe this will help us expand our leadership in identifying and defining the discrete sources that sustain complex arrhythmias," CEO Edward Kerslake said in prepared remarks.
Topera reeled in a $25 million Series C round, 1st reported by MassDevice.com, last spring. First-time backer New Enterprise Assoc. led the round, which also included an unnamed "strategic industry partner."
Intersect ENT enrolls the 1st patient in its PROGRESS study, aiming to expand the patient population...
Innovative needle design to enhance patient safety.
Medtronic taps Dr. Elizabeth Nabel, president of Brigham & Women's Faulkner Hospital in Boston,...
NxStage Medical wins FDA clearance to market its OneSite single needle dialysis technology for use...